董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Luke Beshar | 男 | Director | 62 | 51.63万美元 | 未持股 | 2021-04-28 |
| Helen Tayton Martin | 女 | Director | 54 | 49.93万美元 | 未持股 | 2021-04-28 |
| Scott Myers | 男 | Director | 55 | 未披露 | 未持股 | 2021-04-28 |
| Helen Tayton Martin | 女 | Director | 54 | 未披露 | 未持股 | 2021-04-28 |
| Michael Kamarck | 男 | Director | 70 | 82.48万美元 | 未持股 | 2021-04-28 |
| Paul Walker | 男 | Director | 46 | 未披露 | 未持股 | 2021-04-28 |
| Jan Skvarka | 男 | Director,President and Chief Executive Officer | 54 | 679.51万美元 | 未持股 | 2021-04-28 |
| Paolo Pucci | 男 | Director | 59 | 85.74万美元 | 未持股 | 2021-04-28 |
| Paul Walker | 男 | Director | 46 | 43.90万美元 | 未持股 | 2021-04-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Uger | 男 | Chief Scientific Officer | 50 | 308.85万美元 | 未持股 | 2021-04-28 |
| Penka Petrova | 男 | Chief Development Officer | 53 | 194.95万美元 | 未持股 | 2021-04-28 |
| James Parsons | 男 | Chief Financial Officer | 55 | 233.82万美元 | 未持股 | 2021-04-28 |
| Jan Skvarka | 男 | Director,President and Chief Executive Officer | 54 | 679.51万美元 | 未持股 | 2021-04-28 |
| Ingmar Bruns | -- | Chief Medical Officer | 46 | 488.52万美元 | 未持股 | 2021-04-28 |
| Rosemary Harrison | 女 | Senior Vice President, Corporate Development and Strategy | 38 | 未披露 | 未持股 | 2021-04-28 |
董事简历
中英对照 | 中文 | 英文- Luke Beshar
-
Luke Beshar是一个独立的生物技术顾问和财务专家。2007年11月至2015年2月，他最近担任NPS Pharmaceuticals, Inc.（一家全球性的 Biopharmaceuticals, Inc）的执行/高级副总裁兼首席财务官。Beshar先生也任职REGENXBIO Inc., Entera Bio Ltd. 和Sancilio Pharmaceuticals Company, Inc.的董事会。
Luke Beshar is an independent biotechnology consultant and financial expert. Mr. Beshar is a former chief financial officer of various public and private companies and has more than 30 years of general and financial management experience. Mr. Beshar has served as a director of REGENXBIO Inc., a publicly held gene therapy company, since May 2015 and is currently chair of its audit committee. Mr. Beshar has served as a director of Protara Therapeutics, Inc., a publicly held company focused on immune-oncology and rare diseases, since October 2018 and is currently chairman of its board of directors and chair of its nominating and corporate governance committee. Mr. Beshar was most recently the Executive/Senior Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a global biopharmaceutical company from November 2007 to February 2015. Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a life sciences company, from December 2002 to November 2007. Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a Certified Public Accountant. Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.As an independent director, Mr. Beshar supervises our management and helps to ensure compliance with our corporate governance policies and standards. - Luke Beshar是一个独立的生物技术顾问和财务专家。2007年11月至2015年2月，他最近担任NPS Pharmaceuticals, Inc.（一家全球性的 Biopharmaceuticals, Inc）的执行/高级副总裁兼首席财务官。Beshar先生也任职REGENXBIO Inc., Entera Bio Ltd. 和Sancilio Pharmaceuticals Company, Inc.的董事会。
- Luke Beshar is an independent biotechnology consultant and financial expert. Mr. Beshar is a former chief financial officer of various public and private companies and has more than 30 years of general and financial management experience. Mr. Beshar has served as a director of REGENXBIO Inc., a publicly held gene therapy company, since May 2015 and is currently chair of its audit committee. Mr. Beshar has served as a director of Protara Therapeutics, Inc., a publicly held company focused on immune-oncology and rare diseases, since October 2018 and is currently chairman of its board of directors and chair of its nominating and corporate governance committee. Mr. Beshar was most recently the Executive/Senior Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a global biopharmaceutical company from November 2007 to February 2015. Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a life sciences company, from December 2002 to November 2007. Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a Certified Public Accountant. Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.As an independent director, Mr. Beshar supervises our management and helps to ensure compliance with our corporate governance policies and standards.
- Helen Tayton Martin
-
Helen Tayton Martin自2008年7月起担任公司首席运营官；是公司联合创始人之一。她负责公司的研发规划监管、业务开发和商业活动，包括与GSK的战略合伙企业。Tayton-Martin有着23年多的工作经验，在临床前和临床学科的发展、外包、战略规划、尽职调查和业务发展的制药、生物技术和咨询环境领域任职过。她是Adaptimmune联合创始人，之前曾在Avidex Limited subsequently Medigene任职，2005年到2008年负责癌症和HIV疗法可溶解遵行方案的商业开发。Tayton-Martin持有英国the University of Bristol分子免疫学博士学位以及Harvard Business School工商管理硕士学位。
Helen Tayton Martin, Ph.D.,Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017 having served as Chief Operating Officer since 2008 a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline LSE/NYSE: GSK ("GSK"). She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School. - Helen Tayton Martin自2008年7月起担任公司首席运营官；是公司联合创始人之一。她负责公司的研发规划监管、业务开发和商业活动，包括与GSK的战略合伙企业。Tayton-Martin有着23年多的工作经验，在临床前和临床学科的发展、外包、战略规划、尽职调查和业务发展的制药、生物技术和咨询环境领域任职过。她是Adaptimmune联合创始人，之前曾在Avidex Limited subsequently Medigene任职，2005年到2008年负责癌症和HIV疗法可溶解遵行方案的商业开发。Tayton-Martin持有英国the University of Bristol分子免疫学博士学位以及Harvard Business School工商管理硕士学位。
- Helen Tayton Martin, Ph.D.,Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017 having served as Chief Operating Officer since 2008 a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline LSE/NYSE: GSK ("GSK"). She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.
- Scott Myers
-
Scott Myers自2016年4月起担任公司董事。Myers从2011年9月到2015年7月担任Aerocrine AB（一家生物制药公司，2015年7月被Circassia Pharmaceuticals plc收购）首席执行官。Myers从2007年1月到2011年9月担任UCB S.A.（一家生物制药公司）副总裁。Myers从2005年12月到2007年1月担任DOV Pharmaceutical（一家生物技术公司）首席商务官；2000年到2005年担任Johnson & Johnson高级副总裁和总经理。此外，Myers从2012年4月到2014年4月担任Orexo AB（一家制药公司）董事；现任EQT（投资基金）工业顾问。Myers持有Northwestern University生物学文学学士学位；the Kellogg Graduate School of Management at Northwestern University工商管理硕士学位。
Scott Myers was appointed as a member of our Board on April 28 2021. Most recently, Mr. Myers was the Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals, Inc., a pharmaceutical company, where he led its turnaround and strategic exit to Covis Pharma, S.à.r.l., a pharmaceutical company, in November 2020. Mr. Myers has served as Chairman of the board of directors of Rainier Therapeutics, Inc., an oncology biotechnology company focused on late-stage bladder cancer, from June 2018 to January 2020 and served as its Chief Executive Officer from September 2018 to January 2020. Mr. Myers led Rainier's asset sale of vofatamab to Fusion Pharmaceuticals Inc. Prior to Rainier, Mr. Myers served as Chief Executive Officer, President and Director for Cascadian Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle Genetics in March 2018. Mr. Myers is an independent director on the board of directors of Selecta Biosciences Nasdaq: SELB and Harpoon Therapeutics, Inc. (Nasdaq: HARP). Mr. Myers holds a B.A. in Biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago.As an independent director, Mr. Myers supervises our management and helps to ensure compliance with our corporate governance policies and standards. - Scott Myers自2016年4月起担任公司董事。Myers从2011年9月到2015年7月担任Aerocrine AB（一家生物制药公司，2015年7月被Circassia Pharmaceuticals plc收购）首席执行官。Myers从2007年1月到2011年9月担任UCB S.A.（一家生物制药公司）副总裁。Myers从2005年12月到2007年1月担任DOV Pharmaceutical（一家生物技术公司）首席商务官；2000年到2005年担任Johnson & Johnson高级副总裁和总经理。此外，Myers从2012年4月到2014年4月担任Orexo AB（一家制药公司）董事；现任EQT（投资基金）工业顾问。Myers持有Northwestern University生物学文学学士学位；the Kellogg Graduate School of Management at Northwestern University工商管理硕士学位。
- Scott Myers was appointed as a member of our Board on April 28 2021. Most recently, Mr. Myers was the Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals, Inc., a pharmaceutical company, where he led its turnaround and strategic exit to Covis Pharma, S.à.r.l., a pharmaceutical company, in November 2020. Mr. Myers has served as Chairman of the board of directors of Rainier Therapeutics, Inc., an oncology biotechnology company focused on late-stage bladder cancer, from June 2018 to January 2020 and served as its Chief Executive Officer from September 2018 to January 2020. Mr. Myers led Rainier's asset sale of vofatamab to Fusion Pharmaceuticals Inc. Prior to Rainier, Mr. Myers served as Chief Executive Officer, President and Director for Cascadian Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle Genetics in March 2018. Mr. Myers is an independent director on the board of directors of Selecta Biosciences Nasdaq: SELB and Harpoon Therapeutics, Inc. (Nasdaq: HARP). Mr. Myers holds a B.A. in Biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago.As an independent director, Mr. Myers supervises our management and helps to ensure compliance with our corporate governance policies and standards.
- Helen Tayton Martin
-
Adaptimmune公司的首席商务官Helen Tayton Martin在制药、生物技术和咨询领域拥有超过25年的经验，涉及临床前和临床开发、外包、战略规划、尽职调查和业务开发等多个领域。她曾共同创立Adaptimmune公司（原公司，Avidex Limited），在那里她曾负责癌症和艾滋病毒治疗的可溶性TCR计划的商业开发（从2005年到2008年）。Tayton-Martin博士于2017年3月过渡到Adaptimmune的首席商务官，自2008年起担任其首席运营官，负责监督公司所有业务从5名员工到300名员工的过渡，通过跨大西洋增长，多个临床，学术和商业合作以及私人和公共融资，直到其纳斯达克IPO。
Helen Tayton Martin has been the Chief Business Officer at Adaptimmune Therapeutics since March 2017 a publicly-listed biotechnology company focused on cancer immunotherapy and a leader in T-cell therapy. Dr. Tayton-Martin co-founded Adaptimmune from the former company Avidex Limited, and served as its Chief Operating Officer from inception in 2008 to March 2017. As CBO she is responsible for business development, alliance management, commercial planning and oversight of the research organisation. Prior to Adaptimmune and its predecessor companies, Dr. Tayton-Martin began her industry career in vaccine and oncology clinical development with Pasteur-Merieux and Sandoz respectively, before spending 10 years in drug development consultancy with UK-based Technomark Consulting. She has a PhD in molecular immunology and an MBA from London Business School.As an independent director, Dr. Tayton-Martin supervises our management and helps to ensure compliance with our corporate governance policies and standards. - Adaptimmune公司的首席商务官Helen Tayton Martin在制药、生物技术和咨询领域拥有超过25年的经验，涉及临床前和临床开发、外包、战略规划、尽职调查和业务开发等多个领域。她曾共同创立Adaptimmune公司（原公司，Avidex Limited），在那里她曾负责癌症和艾滋病毒治疗的可溶性TCR计划的商业开发（从2005年到2008年）。Tayton-Martin博士于2017年3月过渡到Adaptimmune的首席商务官，自2008年起担任其首席运营官，负责监督公司所有业务从5名员工到300名员工的过渡，通过跨大西洋增长，多个临床，学术和商业合作以及私人和公共融资，直到其纳斯达克IPO。
- Helen Tayton Martin has been the Chief Business Officer at Adaptimmune Therapeutics since March 2017 a publicly-listed biotechnology company focused on cancer immunotherapy and a leader in T-cell therapy. Dr. Tayton-Martin co-founded Adaptimmune from the former company Avidex Limited, and served as its Chief Operating Officer from inception in 2008 to March 2017. As CBO she is responsible for business development, alliance management, commercial planning and oversight of the research organisation. Prior to Adaptimmune and its predecessor companies, Dr. Tayton-Martin began her industry career in vaccine and oncology clinical development with Pasteur-Merieux and Sandoz respectively, before spending 10 years in drug development consultancy with UK-based Technomark Consulting. She has a PhD in molecular immunology and an MBA from London Business School.As an independent director, Dr. Tayton-Martin supervises our management and helps to ensure compliance with our corporate governance policies and standards.
- Michael Kamarck
-
Michael Kamarck自2017年6月起担任我们的首席技术官。2013年9月至2017年5月，Kamarck博士担任Willow Creek Biotech Consulting的负责人，为众多大型和小型公司提供生物技术技术运营领域的咨询。从2014年3月到2014年12月，他曾担任Sanofi公司的治疗性单克隆抗体组织的临时负责人，在那里他曾领导Sanofi公司和Genzyme公司的生物技术资产的整合和重组。从2009年12月到2012年3月，Kamarck博士担任默克生物风险投资公司（Merck BioVentures）的总裁，并担任默克公司（默克制药公司）疫苗和生物制品制造的高级副总裁。从2001年5月到2009年10月，他曾担任Wyeth Pharmaceuticals公司（Wyeth公司）的多种高级执行职务，包括总裁，负责技术运营和产品供应，也曾负责Wyeth公司的所有业务的全球技术运营。Kamarck博士还担任惠氏管理委员会成员。任职Wyeth公司之前，他曾任职Bayer AG17年，担任多种技术和领导职务。Kamarck博士曾分别于2013年1月至2015年6月和2016年7月至2017年10月担任Omni Bio Pharmaceutical，Inc.和Unilife Corporation的董事会成员。Kamarck博士在欧柏林学院（Oberlin College）获得学士学位，在麻省理工学院（MIT）获得博士学位，并且是耶鲁大学（Yale University）的白血病学会会员。
Michael Kamarck has over thirty years of experience in biologics manufacturing and currently serves as Chief Technology Officer for Vir Biotechnology, Inc., where he manages a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19 influenza and hepatitis B. Before joining Vir, Dr. Kamarck was Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures where he was instrumental in establishing Merck's global biosimilars business. Prior to Merck, Dr. Kamarck held various senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply. Dr. Kamarck received his B.A. from Oberlin College, his Ph.D. in biochemistry from Massachusetts Institute of Technology and was a Leukemia Society Fellow at Yale University.As an independent director, Dr. Kamarck supervises our management and helps to ensure compliance with our corporate governance policies and standards. - Michael Kamarck自2017年6月起担任我们的首席技术官。2013年9月至2017年5月，Kamarck博士担任Willow Creek Biotech Consulting的负责人，为众多大型和小型公司提供生物技术技术运营领域的咨询。从2014年3月到2014年12月，他曾担任Sanofi公司的治疗性单克隆抗体组织的临时负责人，在那里他曾领导Sanofi公司和Genzyme公司的生物技术资产的整合和重组。从2009年12月到2012年3月，Kamarck博士担任默克生物风险投资公司（Merck BioVentures）的总裁，并担任默克公司（默克制药公司）疫苗和生物制品制造的高级副总裁。从2001年5月到2009年10月，他曾担任Wyeth Pharmaceuticals公司（Wyeth公司）的多种高级执行职务，包括总裁，负责技术运营和产品供应，也曾负责Wyeth公司的所有业务的全球技术运营。Kamarck博士还担任惠氏管理委员会成员。任职Wyeth公司之前，他曾任职Bayer AG17年，担任多种技术和领导职务。Kamarck博士曾分别于2013年1月至2015年6月和2016年7月至2017年10月担任Omni Bio Pharmaceutical，Inc.和Unilife Corporation的董事会成员。Kamarck博士在欧柏林学院（Oberlin College）获得学士学位，在麻省理工学院（MIT）获得博士学位，并且是耶鲁大学（Yale University）的白血病学会会员。
- Michael Kamarck has over thirty years of experience in biologics manufacturing and currently serves as Chief Technology Officer for Vir Biotechnology, Inc., where he manages a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19 influenza and hepatitis B. Before joining Vir, Dr. Kamarck was Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures where he was instrumental in establishing Merck's global biosimilars business. Prior to Merck, Dr. Kamarck held various senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply. Dr. Kamarck received his B.A. from Oberlin College, his Ph.D. in biochemistry from Massachusetts Institute of Technology and was a Leukemia Society Fellow at Yale University.As an independent director, Dr. Kamarck supervises our management and helps to ensure compliance with our corporate governance policies and standards.
- Paul Walker
-
Paul Walker是New Enterprise Associates NEA的普通合伙人，该公司是一家投资公司，专注于风险资本和成长型股权投资，自2008年以来，他一直专注于后期生物技术和生命科学投资。Walker先生还担任Allakos和Tracon Pharmaceuticals的董事会成员。
Paul Walker is a general partner of New Enterprise Associates NEA, an investment firm focused on venture capital and growth equity investments, where he has specialized in later-stage biotechnology and life sciences investments since 2008. Mr. Walker also sits on the boards of Allakos, Inc.As an independent director, Mr. Walker supervises our management and helps to ensure compliance with our corporate governance policies and standards. - Paul Walker是New Enterprise Associates NEA的普通合伙人，该公司是一家投资公司，专注于风险资本和成长型股权投资，自2008年以来，他一直专注于后期生物技术和生命科学投资。Walker先生还担任Allakos和Tracon Pharmaceuticals的董事会成员。
- Paul Walker is a general partner of New Enterprise Associates NEA, an investment firm focused on venture capital and growth equity investments, where he has specialized in later-stage biotechnology and life sciences investments since 2008. Mr. Walker also sits on the boards of Allakos, Inc.As an independent director, Mr. Walker supervises our management and helps to ensure compliance with our corporate governance policies and standards.
- Jan Skvarka
-
Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
Jan Skvarka has been the President and Chief Executive Officer of Trillium since September 25 2019. Prior to joining Trillium, Dr. Skvarka served as the President and CEO of Tal Medical, a clinical-stage neuroscience company in Boston, Massachusetts, from 2014 until 2018. Before Tal, Dr. Skvarka spent 14 years with Bain & Company, Boston as a healthcare consultant. He was partner in the Healthcare practice from 2007 until 2013 with a focus on pharmaceutical, biotechnology and medical technology companies. Earlier in his career, Dr. Skvarka worked in the corporate finance arm of Price Waterhouse in London, UK and Vienna, Austria.As President and Chief Executive Officer, Dr. Skvarka is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Skvarka participates in management oversight and helps to ensure compliance with our corporate governance policies and standards. - Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
- Jan Skvarka has been the President and Chief Executive Officer of Trillium since September 25 2019. Prior to joining Trillium, Dr. Skvarka served as the President and CEO of Tal Medical, a clinical-stage neuroscience company in Boston, Massachusetts, from 2014 until 2018. Before Tal, Dr. Skvarka spent 14 years with Bain & Company, Boston as a healthcare consultant. He was partner in the Healthcare practice from 2007 until 2013 with a focus on pharmaceutical, biotechnology and medical technology companies. Earlier in his career, Dr. Skvarka worked in the corporate finance arm of Price Waterhouse in London, UK and Vienna, Austria.As President and Chief Executive Officer, Dr. Skvarka is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Skvarka participates in management oversight and helps to ensure compliance with our corporate governance policies and standards.
- Paolo Pucci
-
Paolo Pucci，2008年6月，他从Bayer A.G。跳槽到ArQule，并担任首席行政官和董事会成员，他在Bayer A.G。担任高级副总裁和Bayer-Schering全球肿瘤治疗制药商业机构总裁；此前，他是Bayer药厂的全球性专业经营单位的高级副总裁，美国制药业务的总裁和Bayer制药公司的全球管理委员会成员；在Bayer，他负责Nexavar sorafenib（一种用于治疗肝脏和肾脏癌的口服多激酶抑制剂）相关业务。这些活动包括临床开发、监管部门的审查、企业联盟管理、产品发布和市场营销。2001年，他加入Bayer，担任意大利地区的制药业务。在加入Bayer之前，他在Eli Lilly任职，并且职务越来越高，后成为Eli Lilly Sweden AB的管理董事。在Lilly工作的时候，他主要负责业务、销售、市场营销和战略规划。2011年11月，他被任命为Dyax Corp的董事，目前他在Dyax Corp担任独立董事、审核委员会成员和管理、提名委员会主席。2013年4月，他被任命为Algeta ASA（位于挪威奥斯陆的肿瘤研究公司，）董事会成员，后担任独立董事和审核委员会成员直到Algeta被Bayer A.G收购。他获有芝加哥大学的工商管理硕士学位，还是意大利那不勒斯大学研究生，是意大利特许Dottore Commercialista。
Paolo Pucci,Extensive healthcare industry experience through his CEO role at ArQule and senior management roles at prior multinational companies.Holds both undergraduate and graduate degrees in accounting and finance.International work experience at two major global companies.Experienced in operations oversight for several major pharmaceutical companies including the management of Regulatory Affairs associated with each company's portfolio of products.Extensive experience marketing to customers and promoting goods and services through his career.Actively participated in several mergers and acquisitions, strategic business partnerships and divestitures during his career at ArQule, including its acquisition by Merck & Co.Developed executive leadership skills as CEO of a publicly-traded company and various senior roles at large multinational companies.Mr. Pucci previously served on the Board of Directors for Dyax, Inc., Algeta ASA, New Link Genetics Inc., Arqule, Inc. and was also Lead Independent Director at Trillium Therapeutics until it was acquired by Pfizer Inc. in November 2021. He now is a member of the publicly-held life sciences companies Merus N.V. and Replimune Group Inc. Mr. Pucci holds an undergraduate degree in economics and accounting from the Università degli Studi di Napoli Federico II and Master of Business Administration from the University of Chicago Booth. - Paolo Pucci，2008年6月，他从Bayer A.G。跳槽到ArQule，并担任首席行政官和董事会成员，他在Bayer A.G。担任高级副总裁和Bayer-Schering全球肿瘤治疗制药商业机构总裁；此前，他是Bayer药厂的全球性专业经营单位的高级副总裁，美国制药业务的总裁和Bayer制药公司的全球管理委员会成员；在Bayer，他负责Nexavar sorafenib（一种用于治疗肝脏和肾脏癌的口服多激酶抑制剂）相关业务。这些活动包括临床开发、监管部门的审查、企业联盟管理、产品发布和市场营销。2001年，他加入Bayer，担任意大利地区的制药业务。在加入Bayer之前，他在Eli Lilly任职，并且职务越来越高，后成为Eli Lilly Sweden AB的管理董事。在Lilly工作的时候，他主要负责业务、销售、市场营销和战略规划。2011年11月，他被任命为Dyax Corp的董事，目前他在Dyax Corp担任独立董事、审核委员会成员和管理、提名委员会主席。2013年4月，他被任命为Algeta ASA（位于挪威奥斯陆的肿瘤研究公司，）董事会成员，后担任独立董事和审核委员会成员直到Algeta被Bayer A.G收购。他获有芝加哥大学的工商管理硕士学位，还是意大利那不勒斯大学研究生，是意大利特许Dottore Commercialista。
- Paolo Pucci,Extensive healthcare industry experience through his CEO role at ArQule and senior management roles at prior multinational companies.Holds both undergraduate and graduate degrees in accounting and finance.International work experience at two major global companies.Experienced in operations oversight for several major pharmaceutical companies including the management of Regulatory Affairs associated with each company's portfolio of products.Extensive experience marketing to customers and promoting goods and services through his career.Actively participated in several mergers and acquisitions, strategic business partnerships and divestitures during his career at ArQule, including its acquisition by Merck & Co.Developed executive leadership skills as CEO of a publicly-traded company and various senior roles at large multinational companies.Mr. Pucci previously served on the Board of Directors for Dyax, Inc., Algeta ASA, New Link Genetics Inc., Arqule, Inc. and was also Lead Independent Director at Trillium Therapeutics until it was acquired by Pfizer Inc. in November 2021. He now is a member of the publicly-held life sciences companies Merus N.V. and Replimune Group Inc. Mr. Pucci holds an undergraduate degree in economics and accounting from the Università degli Studi di Napoli Federico II and Master of Business Administration from the University of Chicago Booth.
- Paul Walker
-
Paul Walker，自2010年5月在公司董事会任职，自2008年4月，Walker先生担任新企业协会（New Enterprise Associates）的合作伙伴，这是一家投资公司，专注于风险投资和成长型股权投资，他后期主要集中在生物技术和生命科学投资。从2001年1月至2008年3月Walker先生曾在MPM Capital，一家生命科学风险资本公司工作，是MPM BioEquities基金的普通合伙人。从1996年7月至2000年12月Walker先生曾担任富兰克林邓普顿投资（Franklin Templeton Investments）组合经理。 Walker先生从加州大学圣地亚哥分校（the University of California at San Diego）获生物化学和细胞生物学学士学位。Walker先生是特许金融分析师。
Paul Walker has served on our Board since September 2014. Mr. Walker has been a partner of New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since April 2008 where Mr. Walker focuses on later-stage biotechnology and life sciences investments. From January 2001 to March 2008 Mr. Walker worked at MPM Capital, a life sciences venture capital firm, where he specialized in public, PIPE and mezzanine-stage life sciences investing as a general partner with the MPM BioEquities Fund. From July 1996 to December 2000 Mr. Walker served as a portfolio manager at Franklin Resources, Inc., a global investment management organization known as Franklin Templeton Investments. Mr. Walker was a member of the board of directors of TESARO, Inc., an oncology-focused biopharmaceutical company, from May 2010 to May 2014 and is a board observer of Sunesis Pharmaceuticals, Inc., and manages a number of NEA’s other late-stage and public investments. In addition, Mr. Walker is a member of the board of directors of Allakos, Inc., a privately held company focused on the development of drugs to treat eosinophil and mast-cell driven diseases and is a member of the board of directors of Trillium Therapeutics, Inc., a public clinical stage immune-oncology company developing therapies for the treatment of cancer. Mr. Walker received a B.S. in biochemistry and cell biology from the University of California at San Diego and holds the Chartered Financial Analyst designation. - Paul Walker，自2010年5月在公司董事会任职，自2008年4月，Walker先生担任新企业协会（New Enterprise Associates）的合作伙伴，这是一家投资公司，专注于风险投资和成长型股权投资，他后期主要集中在生物技术和生命科学投资。从2001年1月至2008年3月Walker先生曾在MPM Capital，一家生命科学风险资本公司工作，是MPM BioEquities基金的普通合伙人。从1996年7月至2000年12月Walker先生曾担任富兰克林邓普顿投资（Franklin Templeton Investments）组合经理。 Walker先生从加州大学圣地亚哥分校（the University of California at San Diego）获生物化学和细胞生物学学士学位。Walker先生是特许金融分析师。
- Paul Walker has served on our Board since September 2014. Mr. Walker has been a partner of New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since April 2008 where Mr. Walker focuses on later-stage biotechnology and life sciences investments. From January 2001 to March 2008 Mr. Walker worked at MPM Capital, a life sciences venture capital firm, where he specialized in public, PIPE and mezzanine-stage life sciences investing as a general partner with the MPM BioEquities Fund. From July 1996 to December 2000 Mr. Walker served as a portfolio manager at Franklin Resources, Inc., a global investment management organization known as Franklin Templeton Investments. Mr. Walker was a member of the board of directors of TESARO, Inc., an oncology-focused biopharmaceutical company, from May 2010 to May 2014 and is a board observer of Sunesis Pharmaceuticals, Inc., and manages a number of NEA’s other late-stage and public investments. In addition, Mr. Walker is a member of the board of directors of Allakos, Inc., a privately held company focused on the development of drugs to treat eosinophil and mast-cell driven diseases and is a member of the board of directors of Trillium Therapeutics, Inc., a public clinical stage immune-oncology company developing therapies for the treatment of cancer. Mr. Walker received a B.S. in biochemistry and cell biology from the University of California at San Diego and holds the Chartered Financial Analyst designation.
高管简历
中英对照 | 中文 | 英文- Robert Uger
Robert Uger，他是Trillium公司的首席科学官（2013年4月9日以来），也曾担任Trillium Privateco公司的研究副总裁（2003年以来）。加入Trillium公司之前，他曾任职Aventis Pasteur公司，在那里他曾担任高级研究科学家，参与癌症疫苗的研究。
Robert Uger has been the Chief Scientific Officer of Trillium since April 9 2013 and was the Vice President, Research of Trillium Privateco prior thereto from 2003.As Chief Scientific Officer, Dr. Uger is responsible for developing and implementing our scientific direction, and oversees both internal product development and external research and development programs.Dr. Uger also served on the board of directors from April 29 2019 to February 6 2020.- Robert Uger，他是Trillium公司的首席科学官（2013年4月9日以来），也曾担任Trillium Privateco公司的研究副总裁（2003年以来）。加入Trillium公司之前，他曾任职Aventis Pasteur公司，在那里他曾担任高级研究科学家，参与癌症疫苗的研究。
- Robert Uger has been the Chief Scientific Officer of Trillium since April 9 2013 and was the Vice President, Research of Trillium Privateco prior thereto from 2003.As Chief Scientific Officer, Dr. Uger is responsible for developing and implementing our scientific direction, and oversees both internal product development and external research and development programs.Dr. Uger also served on the board of directors from April 29 2019 to February 6 2020.
- Penka Petrova
Penka Petrova，他是Trillium公司的药物开发副总裁（2013年4月9日以来），也曾担任Trillium Privateco公司的药物开发董事（从2011年6月到2013年3月）。他于2003年加入Trillium Privateco公司，此前曾任职Prescient Neuropharma公司。
Penka Petrova has been the Chief Development Officer of Trillium since May 29 2015 and was the Vice President, Drug Development from April 2013 to May 2015. Dr. Petrova joined Trillium Privateco in 2003.As Chief Development Officer, Dr. Petrova is responsible for managing Trillium formal drug development efforts, including all outsourced activities to contract manufacturers and contract research organizations.- Penka Petrova，他是Trillium公司的药物开发副总裁（2013年4月9日以来），也曾担任Trillium Privateco公司的药物开发董事（从2011年6月到2013年3月）。他于2003年加入Trillium Privateco公司，此前曾任职Prescient Neuropharma公司。
- Penka Petrova has been the Chief Development Officer of Trillium since May 29 2015 and was the Vice President, Drug Development from April 2013 to May 2015. Dr. Petrova joined Trillium Privateco in 2003.As Chief Development Officer, Dr. Petrova is responsible for managing Trillium formal drug development efforts, including all outsourced activities to contract manufacturers and contract research organizations.
- James Parsons
James Parsons，自2015年10月起担任董事会成员。此前，从2010年10月到2014年5月，他担任Diamedica Therapeutics Inc.的财务副总裁。自2011年8月起，他担任Trillium Therapeutics Inc.(纳斯达克上市的免疫肿瘤公司)的首席财务官和公司秘书。他担任Sernova Corp.(在TSX Venture Exchange上市)的董事会成员和审计委员会主席。自2000年以来，他一直担任生命科学行业的首席财务官，具有治疗学、诊断和设备方面的经验。他持有the University of Waterloo的会计硕士学位，是一名特许职业会计师和特许会计师。Parsons先生是加拿大安大略省的居民。
James Parsons has been the Chief Financial Officer of Trillium since August 25 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014. Mr. Parsons sits on the board of Sernova Corp and DiaMedica Therapeutics, Inc.As Chief Financial Officer, Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration.- James Parsons，自2015年10月起担任董事会成员。此前，从2010年10月到2014年5月，他担任Diamedica Therapeutics Inc.的财务副总裁。自2011年8月起，他担任Trillium Therapeutics Inc.(纳斯达克上市的免疫肿瘤公司)的首席财务官和公司秘书。他担任Sernova Corp.(在TSX Venture Exchange上市)的董事会成员和审计委员会主席。自2000年以来，他一直担任生命科学行业的首席财务官，具有治疗学、诊断和设备方面的经验。他持有the University of Waterloo的会计硕士学位，是一名特许职业会计师和特许会计师。Parsons先生是加拿大安大略省的居民。
- James Parsons has been the Chief Financial Officer of Trillium since August 25 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014. Mr. Parsons sits on the board of Sernova Corp and DiaMedica Therapeutics, Inc.As Chief Financial Officer, Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration.
- Jan Skvarka
Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
Jan Skvarka has been the President and Chief Executive Officer of Trillium since September 25 2019. Prior to joining Trillium, Dr. Skvarka served as the President and CEO of Tal Medical, a clinical-stage neuroscience company in Boston, Massachusetts, from 2014 until 2018. Before Tal, Dr. Skvarka spent 14 years with Bain & Company, Boston as a healthcare consultant. He was partner in the Healthcare practice from 2007 until 2013 with a focus on pharmaceutical, biotechnology and medical technology companies. Earlier in his career, Dr. Skvarka worked in the corporate finance arm of Price Waterhouse in London, UK and Vienna, Austria.As President and Chief Executive Officer, Dr. Skvarka is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Skvarka participates in management oversight and helps to ensure compliance with our corporate governance policies and standards.- Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
- Jan Skvarka has been the President and Chief Executive Officer of Trillium since September 25 2019. Prior to joining Trillium, Dr. Skvarka served as the President and CEO of Tal Medical, a clinical-stage neuroscience company in Boston, Massachusetts, from 2014 until 2018. Before Tal, Dr. Skvarka spent 14 years with Bain & Company, Boston as a healthcare consultant. He was partner in the Healthcare practice from 2007 until 2013 with a focus on pharmaceutical, biotechnology and medical technology companies. Earlier in his career, Dr. Skvarka worked in the corporate finance arm of Price Waterhouse in London, UK and Vienna, Austria.As President and Chief Executive Officer, Dr. Skvarka is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Skvarka participates in management oversight and helps to ensure compliance with our corporate governance policies and standards.
- Ingmar Bruns
Ingmar Bruns自2020年11月2日起担任Trillium的首席医疗官。此前，Bruns博士于2017年10月至2020年11月担任Pieris Pharmaceuticals的高级副总裁兼临床开发主管，并于2013年7月至2017年10月担任Bayer Pharmaceuticals的多个肿瘤资产的临床开发主管，担任首席医疗官，Bruns博士负责我们临床和监管策略的设计和执行。
Ingmar Bruns has been the Chief Medical Officer of Trillium since November 2 2020. Previously, Dr. Bruns was the senior vice president and head of clinical development at Pieris Pharmaceuticals from October 2017 to November 2020 and from July 2013 through October 2017 Dr. Bruns led clinical development of several oncology assets at Bayer Pharmaceuticals.As Chief Medical Officer, Dr. Bruns is responsible for the design and execution of our clinical and regulatory strategy.- Ingmar Bruns自2020年11月2日起担任Trillium的首席医疗官。此前，Bruns博士于2017年10月至2020年11月担任Pieris Pharmaceuticals的高级副总裁兼临床开发主管，并于2013年7月至2017年10月担任Bayer Pharmaceuticals的多个肿瘤资产的临床开发主管，担任首席医疗官，Bruns博士负责我们临床和监管策略的设计和执行。
- Ingmar Bruns has been the Chief Medical Officer of Trillium since November 2 2020. Previously, Dr. Bruns was the senior vice president and head of clinical development at Pieris Pharmaceuticals from October 2017 to November 2020 and from July 2013 through October 2017 Dr. Bruns led clinical development of several oncology assets at Bayer Pharmaceuticals.As Chief Medical Officer, Dr. Bruns is responsible for the design and execution of our clinical and regulatory strategy.
- Rosemary Harrison
Rosemary Harrison于2022年1月加入Tcr2 Therapeutics公司，担任首席业务和战略官。她在制药和生物技术公司的战略规划、投资组合管理和业务发展方面拥有近20年的全球经验。在加入公司之前，她于2020年10月至2021年11月担任副总裁0的企业发展和战略高级副总裁，并于2021年11月领导延龄草治疗以22.2亿美元收购该公司。在此之前，Harrison博士于2018年6月至2019年6月在RA Capital Management担任战略和研究职务，2019年6月至2020年3月担任Imbria Pharmaceuticals罕见病主管，并担任投资组合管理主管2015年3月至2018年5月在诺华生物医学研究所进行战略规划。在她职业生涯的早期，Harrison博士曾在贝恩公司担任顾问，为公司战略和运营计划提供建议。Harrison博士拥有药物设计和开发生物技术学士学位和博士学位。来自昆士兰大学。
Rosemary Harrison joined Tcr2 Therapeutics Inc. company in January 2022 as Chief Business and Strategy Officer. She brings nearly 20 years of global experience working on strategic planning, portfolio management and business development at both pharmaceutical and biotechnology companies. Prior to joining the Company, she was Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics from October 2020 to November 2021 where she led its acquisition by Pfizer for $2.22 billion in November 2021. Before that, Dr. Harrison served in strategic and research roles within RA Capital Management from June 2018 to June 2019 as Head of Rare Diseases at Imbria Pharmaceuticals from June 2019 to March 2020 and as Head of Portfolio Management and Strategic Planning at the Novartis Institutes for Biomedical Research from March 2015 to May 2018. Earlier in her career, Dr Harrison served as a consultant at Bain & Company where she advised on corporate strategic and operational programs. Dr. Harrison holds a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. from The University of Queensland.- Rosemary Harrison于2022年1月加入Tcr2 Therapeutics公司，担任首席业务和战略官。她在制药和生物技术公司的战略规划、投资组合管理和业务发展方面拥有近20年的全球经验。在加入公司之前，她于2020年10月至2021年11月担任副总裁0的企业发展和战略高级副总裁，并于2021年11月领导延龄草治疗以22.2亿美元收购该公司。在此之前，Harrison博士于2018年6月至2019年6月在RA Capital Management担任战略和研究职务，2019年6月至2020年3月担任Imbria Pharmaceuticals罕见病主管，并担任投资组合管理主管2015年3月至2018年5月在诺华生物医学研究所进行战略规划。在她职业生涯的早期，Harrison博士曾在贝恩公司担任顾问，为公司战略和运营计划提供建议。Harrison博士拥有药物设计和开发生物技术学士学位和博士学位。来自昆士兰大学。
- Rosemary Harrison joined Tcr2 Therapeutics Inc. company in January 2022 as Chief Business and Strategy Officer. She brings nearly 20 years of global experience working on strategic planning, portfolio management and business development at both pharmaceutical and biotechnology companies. Prior to joining the Company, she was Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics from October 2020 to November 2021 where she led its acquisition by Pfizer for $2.22 billion in November 2021. Before that, Dr. Harrison served in strategic and research roles within RA Capital Management from June 2018 to June 2019 as Head of Rare Diseases at Imbria Pharmaceuticals from June 2019 to March 2020 and as Head of Portfolio Management and Strategic Planning at the Novartis Institutes for Biomedical Research from March 2015 to May 2018. Earlier in her career, Dr Harrison served as a consultant at Bain & Company where she advised on corporate strategic and operational programs. Dr. Harrison holds a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. from The University of Queensland.